Vol. 3 No. 1 (2023)
Reimbursement Recommendations

Darolutamide (Nubeqa)

decorative image

Published January 23, 2023

Key Messages

  • CADTH recommends that Nubeqa should be reimbursed by public drug plans for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) if certain conditions are met.
  • Nubeqa should only be covered to treat patients with mCSPC who are eligible for chemotherapy and are in relatively good health (i.e., have good performance status). Patients should not have received androgen deprivation therapy (ADT) for metastatic disease for more than 6 months, completed ADT for nonmetastatic disease within the past year, or received other prior systemic therapies for mCSPC.
  • Nubeqa should only be reimbursed if used in combination with docetaxel and ADT and should not be given with other anticancer drugs. It should be prescribed by an oncologist with expertise in the management of prostate cancer, and the price of Nubeqa should be reduced.